INTRODUCTION
Androgen receptor (AR) is a member of the superfamily of hormonal nuclear receptors. 1 Unliganded AR is secured in the cytoplasm by heat-shock proteins. 2 Once exposed to its cognate ligand, the male hormone androgen, AR, becomes activated, separates from heat-shock proteins, and translocates to the nucleus, where it binds to the chromatin at androgen response elements (ARE) to initiate its transcriptional program. This hormone-stimulated AR signaling is important for proper tissue differentiation and homeostasis during prostate development and function. AR signaling, however, is hijacked in prostate tumors, turning into a powerhouse for continuous cancer progression. Thus, the mainstay treatment for metastatic prostate cancer (PCa) is androgen deprivation therapy (ADT). 1 However, despite initial regression of the androgen-dependent tumors (ADPC) on ADT, the disease inevitably comes back in a more aggressive form termed castration-resistant prostate cancer (CRPC). 3 Importantly, although CRPC is resistant to androgen depletion, it continues to depend on AR signaling. Thus, higher affinity, second-generation AR pathway inhibitors, such as enzalutamide and abiraterone, are useful to further delay CRPC progression. 4, 5 Nevertheless, CRPC sustains, ultimately turning into an incurable disease. The search for the mechanisms underlying CRPC progression and treatment resistance will benefit patients who have already exhausted all currently available treatment measures. At the center of such efforts is a comprehensive understanding of AR function.
Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer AR AS A TRANSCRIPTIONAL REPRESSOR
We define AR as a transcriptional repressor only when it binds to DNA at enhancers and/or promoters to directly inhibit genes expression. Genes that are repressed by AR through indirect mechanisms are not considered in this review. We will start out by discussing literatures reporting molecular mechanisms underlying the role of AR as a transcriptional repressor, which are schematically presented in Figure 1 .
HDAC and histone deacetylation
Most nuclear receptors, including AR, can both repress or activate target genes under the instrumentation of essential regulatory cofactors. Gene repression depends on common nuclear receptor corepressors, such as nuclear receptor corepressor (NCoR) and its homolog silencing mediator of retinoid and thyroid receptors (SMRT). 19 NCoR and SMRT are structurally similar; both interact with nuclear receptors through C-terminal domains, while their N-terminal domains recruit histone deacetylases through either direct binding to histone deacetylase 3 (HDAC3), HDAC4, and HDAC5 or indirect interaction with HDAC1 and HDAC2 through Sin3 adaptor protein. 19 Unoccupied HDACs are enzymatically inactive and require stimulation by protein-protein interaction with cofactors. Both SMRT and NCoR carry a conserved N-terminal sequence known as deacetylates activating domain (DAD), which interacts with HDACs, stabilizing their enzymatically active form. 20 Activated HDACs then remove neutral acyls from amino groups on lysine residues of histones 3 and 4, causing positive charge on them. This increases histone's adherence to negatively charged DNA and, thus, facilitates a tight chromatin compaction, which limits DNA accessibility for gene transcription. 21 NCoR has been shown to not only compete with nuclear transcriptional coactivators cAMP-response element (CRE)-binding protein (CREB)-binding protein (CBP) and steroid receptor coactivator-1 (SRC-1) for AR binding but also recruit and activate HDACs at AR target genes, which facilitate local chromatin compaction. 22 In another study, SMRT was shown to mediate transcriptional repression of AR target genes through recruitment of HDACs. 23 Moreover, AR itself has been reported to directly bind to cytoplasmic HDAC7 and transport it into the nuclei, wherein HDAC7 facilitates AR-driven target gene repression.
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LSD1 and lysine demethylation Local histones undergo methylation at various lysine residues, which affects nucleosome accessibility to transcription factors. Three forms of lysine methylation exist: mono-, di-, and trimethylation. Methylated forms of histone 3 lysine 4 (H3K4me1, me2, me3) correlate DNA looping brings AR-repressive complex to proximity with target gene promoter, where HDAC deacetylates H3K27ac, causing chromatin inaccessibility and transcription repression. (b) Gene enhancers are enriched for H3K4me1/2 and gene promoters are enriched for H3K4me3. DHT-AR binding to ARE at target enhancers recruits REST/coREST and LSD1 complex, which demethylates H3K4me1/2 leading to enhancer deactivation. DNA looping further exposes target promoters to LSD1, which catabolizes H3K4me3 demethylation and promoter inactivation. (c) DHT-AR accumulation at target regulatory elements recruits ERG, EZH2, and HDAC repressive complex. HDAC removes acyl groups from H3K27ac, priming it for subsequent trimethylation by EZH2, resulting in epigenetic silencing. (d) AR mediates gene repression through direct binding to Rb. Thus, AR stabilizes Rb interaction with nearby E2F1 transcription activator, inhibiting its transcriptional activity. AR may also itself interact with E2F1 to remove it from chromatin, enabling the recruitment of E2F4 transcriptional repressor. AR: androgen receptor; NCoR: nuclear receptor corepressor; SMRT: silencing mediator of retinoid and thyroid receptors; REST: repressive element 1 silencing transaction. HDAC: histone deacetylase; LSD1: lysine-specific demethylase 1; ERG: ETS-related gene; EZH2: enhancer of zeste homolog 2.
with transcriptional activation. 25, 26 Specifically, H3K4me3 is tightly associated with active gene promoters and H3K4me1 with gene enhancers, while H3K4me2 is described to be present at both promoters and enhancers. [25] [26] [27] [28] Demethylation of activated chromatin represents a potent mechanism for genes repression. Histone-demethylating enzyme, lysine-specific demethylase 1 (LSD1), has been identified as a member of transcription-repressive complex that blocks expression of neuron-specific genes. 28, 29 During gene repression, LSD1 is recruited by repressive element 1 silencing transaction (REST)/coREST repressive complex to the target DNA site. 30 When lysine's side chain amino group becomes mono-or dimethylated, LSD1 reverses lysine methylation through reaction of amine oxidation. The LSD1-catalyzed demethylation is limited to mono-and dimethylated H3K4 substrates because of the biochemical specificity of this reaction. 28 H3K4me3, on the other hand, is metabolized by a group of histone demethylases that contain JmjC domain, which exploits Fe(II)-containing protein cofactor to remove а single methylation group from H3K4me3. 31 The resulting H3K4me2 can further be demethylated by LSD1.
AR has been shown to repress certain target genes, including itself, through engaging LSD1-mediated histone demethylation. 17 Ligand-bound AR coenriches with LSD1 at the ARE-containing enhancer element of the AR gene. This enhancer brings a corepressive complex to the gene promoter through DNA looping, where LSD1 metabolizes demethylation of H3K4me2. The decrease of overall level of histone methylation at the target gene impedes the recruitment of RNA pol II and hence decreases transcription. 17 A more recent work from the same group further demonstrated that coREST, an important LSD1-recruiting protein, cooccupies at the ARE-containing enhancers with LSD1. 32 This study suggests that the ligand-activated AR recruits REST/coREST/LSD1-dependent repressive complex to the AR-regulated enhancers during target genes repression.
32,33
Enhancer of zeste homolog 2 (EZH2) and histone methylation Polycomb repression complex 2 (PRC2), consisted of core subunits suppressor of zeste 12 (SUZ12), embryonic ectoderm development (EED), and EZH2, plays important roles in maintaining embryonic stem cell identity through epigenetic silencing of a large cohort of developmental regulators. 34 EZH2 is the enzymatic subunit of PRC2 that catalyzes histone H3 lysine 27 trimethylation (H3K27me3), a reported mark for repressive histone environment. 35, 36 We have recently reported that EZH2 also plays a polycomb-and methylationindependent role in gene activation, one of its targets being AR, potentiating its function in PCa.
37 EZH2 is among the most upregulated genes in aggressive PCa and its expression is inversely correlated with PCa clinical outcomes.
38 EZH2 behaves as a bona fide oncogene as its overexpression promotes prostate tumorigenesis while its depletion leads to cellular senescence and halts tumor progression. 39 EZH2 has recently been shown to coordinate with AR on transcriptional repression. Through ChIP-seq analysis of the key transcription factors and histone marks, our group identified an integrative transcriptional network involving AR, EZH2, and ETS-related gene-1 (ERG1) in PCa cells. 16 ERG belongs to the ETS family of transcription factors and is frequently fused with the 5' untranslated region of the TMPRSS2 gene in PCa. 40 We showed that ERG cooccupies with AR on many ARE-containing genomic loci to inhibit gene expression, which may be mediated, at least partially, by direct induction of EZH2 expression and recruitment to the target sites for epigenetic silencing. Further, integrating genome-wide AR localization data with androgen-induced gene expression data, we have identified a large number of genes whose expression is directly inhibited by AR but can be rescued through EZH2 inhibition. 18, 41, 42 Collectively, our data establish that EZH2 facilitates AR-transcriptional repression through catalyzing H3K27me3.
An additional report from an independent research group confirms the importance of AR-centered coregulatory network, which wires in ERG and EZH2, in the gene repressive program. 43 Chng and colleagues further identified the collaboration between HDAC2/3 and EZH2, as both enzymes were shown to be recruited to the AR target genes by AR-ERG corepressive complex. HDACs probably cooperate with EZH2 through the removal of acyl groups H3K27ac, which primes H3K27 for subsequent methylation by EZH2.
Retinoblastoma protein (Rb) and E2F family transcription factors
A recent study demonstrated that AR contributes to direct repression of the genes involved in DNA replication in PCa through cooperation with Rb. 44 Gao and colleagues revealed that acute stimulation of AR rapidly suppresses expression of the proliferative genes, such as Minichromosome complex maintenance component 7 (MCM7), FANCI, and lamin B1 (LMNB1) in VCaP cells. Interestingly, most of these AR-repressed regulators of DNA replication contain within their promoter ARE and E2F motifs. E2F transcription factors are controlled by Rb, a prominent oncosuppressor, which inhibits E2F transcriptional activity through direct protein-protein interaction. 45, 46 AR was shown to physically interact with Rb and recruit it to the target genomic loci that locate in proximity to E2F motif. Hence, AR stabilizes the inhibiting interaction between Rb and E2F, abrogating the expression of target genes.
The family of E2F transcription factors includes activator E2F1 and repressor E2F4, which cooperate to facilitate proper transition through cell cycle. 46, 47 AR has been reported to regulate switching between E2F transcription factors. 48 They demonstrated that AR directly represses expression of cyclin B1 in PCa stromal cells through switching E2F family transcription factors. 48 In cyclin B1 promoter, ARE is localized nearby to E2F response element. When AR occupies the ARE site after ligand stimulation, it directly binds to E2F1 and removes it from the E2F response element, which becomes quickly occupied by transcriptional repressor E2F4. This AR-driven enrichment of E2F4 at gene promoter stalks transcription of cyclin B1, causing inhibited proliferation of PCa stromal cells. 48 
AR-REPRESSED GENES AND THEIR ROLES IN PROSTATE CANCER
Since the discovery that PCa depends on androgen signaling 1 and generalization of ADT as a standard of care for PCa patients, 49 research community continuously attempts to understand the transcriptional program governed by AR in PCa. Thus far, the major effort has been primarily focused on AR-activated genes and their roles in PCa development. [49] [50] [51] In this section, we will review the current reports on key AR-repressed genes and their roles in PCa ( Table 1) . We define genes as direct targets of AR only if their regulatory DNA elements contain AREs that are bound by AR.
AR-repressed oncosuppressors
AR signaling regulates normal prostate tissue development and homeostasis, but becomes hijacked during PCa oncogenesis. Thus, androgen deprivation causes cell cycle arrest in PCa cell culture. 52 The communication between AR and mammalian target of rapamycin (mTOR), a molecular master regulator that governs DNA replication during cell cycle, has been addressed in a recent report. 53 AR maintains mTOR signaling through direct repression of oncosuppressor DEP domain-containing mTOR interacting protein (DEPTOR), an endogenous mTOR inhibitor. DEPTOR neutralizes mTORC1 and mTORC2 enzymatic activities through direct interaction. In androgen-dependent LNCAP and VCAP cells, ligand-activated AR enriches to the enhancer ARE region located in 53 Nevertheless, DEPTOR remains repressed in CRPC cells, possibly through an alternative mechanism. Along this line, a recent report demonstrated that, in androgen-independent CRPC tumors, DEPTOR becomes increasingly ubiquitinated and thus degraded because of the upregulated SAG E3 ubiquitin ligase. 54 Epithelial-mesenchymal transition (EMT) stands behind metastatic dissemination, a hallmark of advanced PCa. During EMT, cancer cells lose their epithelial markers, primarily E-cadherin and keratins and upregulate mesenchymal N-cadherin and vimentin. 55 AR may contribute to EMT in PCa via negatively regulating expression of the genes encoding epithelial markers. Liu and colleagues have shown that AR directly represses E-cadherin. Agonist-stimulated AR binds to ARE located in E-cadherin regulatory sequence and recruits corepressor HDAC1, which initiates repressive histone deacetylation. 56 In addition, AR controls the expression of vinculin, a cytoskeleton protein that cooperates with E-cadherin in order to stabilize cell-cell adhesion, thus preventing EMT. AR binds to ARE in the intronic enhancer together with cofactor ERG. AR complexed with ERG brings HDAC and EZH2 holoenzymes, which coordinate exchange of H3K27ac for H3K27me3 and repress vinculin expression. 43 Nevertheless, tumor specimens collected from ADT-treated patients show increased expression of mesenchymal markers. 57 Moreover, in androgen-independent cells that lack endogenous AR, overexpression of ectopic AR inhibits EMT-driven cell invasiveness. 58 This phenomenon can be explained by the cellular context in these cells that overrides AR-downstream effects. For example, androgen-independent PCa cells upregulate Zinc finger E-box-binding protein 1 (ZEB1), a master EMT inducer, which contributes to ADT resistance. 59 ZEB2, another master transcription factor for EMT markers, is also upregulated in these cells and can be indirectly repressed by ectopic AR. 60 Normally, AR is integrated in a tightly organized feedback loop, which stops constitutive AR signaling. However, dysregulation of the feedback response in PCa can cause prolonged overactivation of AR, which in turn enforces tumor growth. Our group has previously identified that AR directly represses the transcription of nephroblastoma overexpressed (NOV), a tumor suppressor arresting cytoplasmic AR from nuclear translocation and inhibiting PCa cells proliferation, migration, and growth. 42 We found that AR directly binds to NOV enhancer, recruiting there a corepressive EZH2 complex. 41 Ligand-activated AR in androgen-dependent PCa cells promotes rapid tumor growth partially through the suppression of NOV and thus the negative feedback loop it mediates. Surprisingly, NOV remains repressed in CRPC and enzalutamide-resistant PCa, probably due to additional mechanisms such as EZH2 upregulation. Although AR targeting might de-repress distinct oncosuppressors in androgendependent PCa, which are manifested by initial regress of tumor growth, the disease eventually reemerges in the form of aggressive, AR-independent CRPC, armed with a range of molecular mechanisms to keep oncosuppressors inhibited.
AR-repressed oncogenes
AR has also been shown to directly repress many oncogenes, which regulate DNA synthesis and cell cycle progression. 17 Accordingly, AR inhibits CCND1, a cyclin D1-encoding gene, through direct binding to its proximal cis enhancer element, 61 where it recruits a corepressor complex, consisted of DAX1, NCoR, and HDACs. 62, 63 Oncogenic cyclin D1 activates cyclin-dependent kinases CDK4 and CDK6, which phosphorylate Rb, causing its degradation. Eradication of phosphorylated Rb unleashes E2F transcriptional activity, necessary for cell cycle progression and proliferation. 64 In PCa, increased cyclin D1 expression has been shown to promote resistance to chemotherapy. 65 A recent report has also confirmed an important role of cyclin D1 in enzalutamide resistance in CRPC patients. 66 Cyclin B1 is another example of AR-repressed oncogene that drives cell cycle progression. The promoter of the cyclin B1 encoding gene, CCNB1, carries both ARE and E2F response elements in proximity one to another. AR recruitment facilitates the switching between E2F activator (E2F1) and E2F repressor (E2F4) and, therefore, inhibits transcription of cyclin B1. 48 Cyclin B1 promotes cell cycle progression through activation of CDK1, which mediates proper progress through G2/M checkpoint. 67 Extensive molecular analyses of clinical specimens and of CRPC murine models suggest that increased expression of cyclin-dependent genes positively correlates with incidence of therapyresistant CRPC tumors. [68] [69] [70] Continuous cell proliferation requires a sustained telomerase (TERT) activity, which is generally induced during oncogenesis. In androgen-dependent PCa cells, AR represses human telomerase reverse transcriptase (hTERT) through direct binding to its gene promoter. 71 The nature of the repressive complex recruited by AR to hTERT remains to be identified. However, it has been reported that mutant AR T877A loses control over hTERT expression, suggesting that in CRPC, which accumulates AR mutants, tumor-repressive function of AR becomes compromised. Moreover, a recent study has demonstrated that AR is downregulated in hTERT high PCa cells, which exhibit cancer stem cell-like properties, in comparison to their hTERT low counterparts. 72 An increased expression of hTERT in aggressive PCa tumors leads to evasion from cell cycle checkpoint control, prompting hTERT targeting for therapeutic evaluation in ADT-resistant prostate cancer. 73 Uncontrolled proliferation in cancer cells commonly relies on constitutively active cellular stimulations by ligands such as cytokines and growth factor. Hepatocyte growth factor/scatter factor (HGF/SF) receptor with tyrosine kinase activity, also known as c-MET, is a well-known oncogene. 74 AR represses MET through direct binding to the ARE element located near the gene promoter. Recruited AR outcompetes transcriptional activator Sp1, whose cognate binding site locates in proximity to ARE. AR-dependent inhibition of Sp1 binding blocks c-MET expression in androgen-responsive PCa cells. 75 In fact, androgen ablation correlates with increased expression of c-MET during CRPC progression. Small-molecule inhibitors specific to c-MET have shown a promising antiproliferative effect for CRPC in preclinical studies. 76 Moreover, anti-c-MET therapeutic agents are currently undergoing clinical trials and have demonstrated preliminary anti-tumor effects in patients with metastatic CRPC. 77 As neuroendocrine prostate cancer (NEPC) features an entire loss of AR expression, 78, 79 and androgen deprivation is known to enable NE differentiation in androgen-sensitive PCa cells, 80 a question arises as to whether AR is capable to repress the expression of NE-driving oncogenes. A recent report has demonstrated that evolution of ADT resistance in PCa coincides with cancer cell transformation from epithelial to neuroendocrine phenotype, driven by lineage plasticity regulated by reprogramming transcription factor sex-determining region Y-box2 (SOX2). 81 Wang et al. 82 studying Pten-null murine PCa model have shown that Sox2-positive luminal PCa cells markedly expand during tumor growth and further increase on castration. AR has been shown to repress SOX2 expression through direct binding to SOX2 cis regulatory element. 83 The exact repressive complex remains unclear. However, AR binding is found to correlate with enrichment for repressive H3K27me3 histone marks at the SOX2 promoter, suggesting the involvement of epigenetic regulation.
In addition to SOX2, AR has recently been shown to directly inhibit the expression of Bruno-like 2 (BRN2, encoded by POU3F2) 84 and paternally expressed 10 (PEG10), 85 which are key regulators of NEPC progression. BRN2 is a target gene for SOX2 transcription factor, and one of the proposed mechanisms, by which AR represses BRN2, is through interference with SOX2 for DNA binding at POU3F2 enhancer. BRN2 has been described as a central and clinically relevant driver of NEPC, as BRN2 is upregulated during NE differentiation and overexpression of BRN2 alone is sufficient to drive resistance to enzalutamide in PCa. On the other hand, PEG10 is a retrotransposonderived gene that is required for cell proliferation and survival and normally expressed during placental development. PEG10, similarly to other cell cycle regulators, is transcribed by E2F1 transcription factor. AR directly represses PEG10 through recruitment and stabilization of inhibitory Rb binding to E2F1. 44 NE transformation, driven by AR loss, correlates with upregulation of PEG10. 85 Accordingly, clinical data confirmed an association between the expressions of PEG10 and NEPC markers. In AR-independent tumors, PEG10 promotes tumor progression at several levels. First, it facilitates a continuous stimulation for expression of proliferative genes, such as cell cycle regulators. Second, PEG10 cooperates with the transforming growth factor-beta (TGF-β) pathway in order to promote NEPC cells invasiveness. 85 Normally, PEG10 is tightly controlled by AR, Rb, and TP53; however, the loss of all three molecules in NEPC upregulates PEG10, leading to an accelerated progression of the lethal disease.
AR-mediated gene repression and its therapeutic implications
AR-mediated gene repression plays important roles in PCa treatment, response, resistance, and progression. During PCa progression to CRPC under ADT, a number of mechanisms have been discovered that bypass androgen dependence, the most frequent one of which is AR hyperactivation through either AR amplification and mutations, 86 or AR cofactors, such as TRIM24, TRIM28, HOTAIR, PADI2, and others. [87] [88] [89] In these tumors, AR continues to induce essential oncogenes and repress tumor suppressor genes, contributing to disease progression in the milieu of low androgen. These CRPC tumors have also been shown to be able to reprogram intracellular molecular signaling in a way to bypass AR dependency. 66, 78, [90] [91] [92] [93] With recent use of high-affinity AR antagonist enzalutamide and androgen synthesis inhibitor abiraterone in the clinic, increasing studies have reported the essential roles of AR-repressed genes in treatment resistance. These drugs appear to immediately contribute to CRPC progression through elimination of the repressive arm of AR-dependent regulation of oncogenes. For example, AR-repressed genes cyclins B1 and D1 are both important for cancer cell expedition through cell cycle. 48, 61 Overexpression of cell cycle regulators CDK4/6, which are activated by cyclin D1, is sufficient to promote enzalutamide resistance, and cotargeting of CDK4/6 can be a promising therapeutic strategy in therapy-resistant CRPC. 94 Clinical characterization of CRPC patients after treatment with enzalutamide and/or abiraterone revealed that cyclin D1 and TGF-β pathways are upregulated in therapy-resistant tumors. 66 In a recent study, we demonstrated that Forkhead Box A1 (FOXA1) loss induces TGF-β signaling, which can be targeted by transforming growth factor beta type I receptor (TGFBR1) inhibitors. 37 Further, we and others have demonstrated in preclinical models that concurrent TGF-β targeting enhances response to enzalutamide and delays the onset of resistance. 95, 96 In addition, data from our group (unpublished) and others have revealed chemokine (CXC motif) receptor 7 (CXCR7), an AR-repressed gene, is upregulated during ADT and contributes to enzalutamide resistance. 97 Another exemplary ARrepressed oncogene is c-MET, which mediates tumor metastasis and has been the center for drug development for the treatment of CRPC. [75] [76] [77] Finally, during CRPC progression, prostate cancer reactivates telomerase TERT. 72 Wild-type AR directly represses TERT expression, and TERT targeting potentiates antitumor efficacy of enzalutamide. 71, 98 The major clinical post-ADT challenges are stemming from emergence of CRPC with aggressive phenotypes, such as neuroendocrine NEPC 78 or double-negative DNPC, which lacks both NEPC-and androgen-dependent CRPC-defining markers. 90 The loss of molecular targets in advance CRPC leaves clinicians with very limited therapeutic armamentarium, 3, 4, [99] [100] [101] rendering NEPC an increasingly abundant lethal disease. This disease can be partially attributed to the restoration of a number of AR-repressed genes on AR elimination in NEPC following strong ADT. 81, [83] [84] [85] For example, AR has been shown to directly repress transcription of SOX2, a reprogramming transcription factor that drives PCa lineage plasticity into enzalutamide-resistant CRPC and NEPC. 81 Moreover, a recent report revealed that AR directly represses a master neural transcription factor BRN2, which promotes enzalutamide-resistant NEPC phenotype in patients. 84 Restored expression of PEG10, another AR-repressed gene, has also been shown to promote progression of NEPC. 85 Collectively, these evidences reinforce the protective role of AR through gene repression in delaying aggressive CRPC and NEPC progression.
AR regulates differentiation of embryonic epithelial cells in urogenital sinus into matured organ during prostate development and maintains homeostatic integrity of prostate tissue in adults. [102] [103] [104] [105] Considering this physiologic role of AR, it is acceptable that, under certain context, AR might, at least partially, restrain aggressive prostate cancer progression. Therapeutic approaches using supraphysiologic levels of testosterone to treat CRPC have been proposed. This idea is appealing considering ADT-related adverse effects, including those caused by testosterone-deficiency, such as anemia, depression, fatigue, and metabolic dysfunctions. In contrary, testosterone administration delivers the opposite, positive effects to patient life quality, advocating for reevaluation of testosterone administration to PCa patients. Despite the lack of controlled clinical studies, some retrospective analyses of previously published data related to therapeutic administration of testosterone suggest that testosterone can mitigate ADT-associated adverse effects without exacerbating PCa. [106] [107] [108] [109] Moreover, preliminary preclinical studies report that testosterone or testosterone metabolites slow down CRPC tumor growth. 110, 111 Mechanistically, this can be supported by the important role of AR in suppressing many oncogenes and nonprostatic transcription factors. Intermittent ADT and supraphysiologic testosterone administration may lead to a balance in killing tumor cells and yet maintaining the prostate lineage. Clearly, more rigorous clinical studies are necessary in order to distil a cohort of CRPC patients that would successfully respond to AR-stimulating therapy.
CONCLUSION
Androgen deprivation and AR-targeted therapies remain as the mainstay treatment for metastatic PCa. The initial survival benefit from utilizing currently approved therapeutic means is undermined by imminent relapse with CRPC. We have already identified a number of mechanisms, such as AR amplification, AR alternative splicing, AR crossing activation with other signaling pathways, or AR bypass, that propagate resistance in CRPC patients to AR-targeted therapies. While the significance of AR-induced gene expression in PCa progression has been extensively reported, the importance of AR-driven gene repression is currently unveiling with the wide application of ADT followed by drug resistance and NEPC progression. In this review, we attempted to critically analyze the current literature on AR-repressed genes and their regulation and function during PCa progression. As a transcriptional repressor, ligand-activated AR binds to the enhancers and/or promoter elements of target genes and mediates assembly of the repressive complexes, including HDACs, LSD1, and EZH2. The resulting histone modifications create repressive environment at the local chromatin, which makes the regulatory elements inaccessible and the gene repressed.
ADT or AR-targeted therapies de-repress both oncosuppressor and oncogenes that are normally inhibited by AR. CRPC appears to adapt and keep oncosuppressors continuously silenced by bypass mechanisms. On the other hand, prosurvival and proliferative oncogenes become activated, driving CRPC to achieve expedited tumor growth and therapy resistance. Accordingly, pharmacological targeting of AR-repressed genes such as c-MET shows promising results in a number of clinical trials for advanced CRPC. 77 AR-repressed genes may be important targets for therapeutic intervention in the postenzalutamide/abiraterone era.
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